Factors Affecting the Response to First-Line Treatments in Patients with Anti-N-Methyl-D-Aspartate Receptor Encephalitis
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background and Purpose Anti-N-methyl-D-aspartate receptor (anti-NMDAR) encephalitis is the most common type of autoimmune encephalitis. This study aimed to explore the possible factors affecting the response to first-line treatments in patients with anti-NMDAR encephalitis. Methods We enrolled 29 patients who were diagnosed as anti-NMDAR encephalitis between January 1, 2015, and June 30, 2018. They were divided into the remission and nonremission groups according to their response to first-line treatments. The demographics, clinical manifestations, main ancillary examinations, follow-up treatments, and prognosis of patients were recorded. The symptoms reported on in this study occurred before treatments or during the course of first-line treatments. Results There were 18 patients (62.07%) in the remission group and 11 patients (37.93%) in the nonremission group. Compared to the remission group, a higher proportion of the patients in the nonremission group exhibited involuntary movements, decreased consciousness, central hypoventilation, lung infection, and hypoalbuminemia. The nonremission group had a high incidence of increased intracranial pressure and significant elevations of the neutrophilto- lymphocyte ratio in peripheral blood (NLR), aspartate aminotransferase, and fibrinogen. Six patients (54.55%) in the nonremission group received second-line immunotherapy. Only one patient (3.45%) died, which was due to multiple- organ failure. Conclusions Anti-NMDAR-encephalitis patients with more symptoms—especially involuntary movements, disturbance of consciousness, central hypoventilation, and accompanying hypoalbuminemia and pulmonary infection—may respond poorly to first-line treatments. Positive second-line immunotherapy therefore needs to be considered. Admission to an intensive-care unit, increased cerebrospinal fluid pressure, and increased NLR might be the significant factors affecting the response to first-line treatments.
Abstract
Background and Purpose Anti-N-methyl-D-aspartate receptor (anti-NMDAR) encephalitis is the most common type of autoimmune encephalitis. This study aimed to explore the possible factors affecting the response to first-line treatments in patients with anti-NMDAR encephalitis. Methods We enrolled 29 patients who were diagnosed as anti-NMDAR encephalitis between January 1, 2015, and June 30, 2018. They were divided into the remission and nonremission groups according to their response to first-line treatments. The demographics, clinical manifestations, main ancillary examinations, follow-up treatments, and prognosis of patients were recorded. The symptoms reported on in this study occurred before treatments or during the course of first-line treatments. Results There were 18 patients (62.07%) in the remission group and 11 patients (37.93%) in the nonremission group. Compared to the remission group, a higher proportion of the patients in the nonremission group exhibited involuntary movements, decreased consciousness, central hypoventilation, lung infection, and hypoalbuminemia. The nonremission group had a high incidence of increased intracranial pressure and significant elevations of the neutrophilto- lymphocyte ratio in peripheral blood (NLR), aspartate aminotransferase, and fibrinogen. Six patients (54.55%) in the nonremission group received second-line immunotherapy. Only one patient (3.45%) died, which was due to multiple- organ failure. Conclusions Anti-NMDAR-encephalitis patients with more symptoms—especially involuntary movements, disturbance of consciousness, central hypoventilation, and accompanying hypoalbuminemia and pulmonary infection—may respond poorly to first-line treatments. Positive second-line immunotherapy therefore needs to be considered. Admission to an intensive-care unit, increased cerebrospinal fluid pressure, and increased NLR might be the significant factors affecting the response to first-line treatments.
참고문헌 (27)
- Dalmau J, "Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma", Ann Neurol, 61, pp.25~36 (2007)
- Dalmau J, "Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis", Lancet Neurol, 10, pp.63~74 (2011)
- Moscato EH, "Acute mechanisms underlying antibody effects in anti-N-methyl-D-aspartate receptor encephalitis", Ann Neurol, 76, pp.108~119 (2014)
- Shin YW, "Treatment strategies for autoimmune encephalitis", Ther Adv Neurol Disorder, 11 (2017)
- Titulaer MJ, "Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis : an observational cohort study", Lancet Neurol, 12, pp.157~165 (2013)
- Balu R, "A score that predicts 1-year functional status in patients with anti-NMDA receptor encephalitis", Neurology, 92, pp.e244~e252 (2019)[DOI]
- Broadley J, "Prognosticating autoimmune encephalitis : a systematic review", J Autoimmun, 96, pp.24~34 (2019)
- Jang Y, "High albumin level is a predictor of favorable response to immunotherapy in autoimmune encephalitis", Sci Rep, 8, pp.1012~ (2018)
- Zeng Z, "Prediction of neutrophil-to-lymphocyte ratio in the diagnosis and progression of autoimmune encephalitis", Neurosci Lett, 694, pp.129~135 (2019)
- Graus F, "A clinical approach to diagnosis of autoimmune encephalitis", Lancet Neurol, 15, pp.391~404 (2016)
- Wang Y, "Anti-N-methyl-d-aspartate receptor encephalitis in children of Central South China : clinical features, treatment, influencing factors, and outcomes", J Neuroimmunol, 312, pp.59~65 (2017)
- Zhang Y, "Clinical characteristics and prognosis of severe anti-N-methyl-D-aspartate receptor encephalitis patients", Neurocrit Care, 29, pp.264~272 (2018)
- Duan BC, "Variations of movement disorders in anti-N-methyl-D-aspartate receptor encephalitis: a nationwide study in Taiwan", Medicine (Baltimore), 95, pp.e4365~ (2016)
- Vural A, "Central neurogenic hyperventilation in anti-NMDA receptor encephalitis", Intern Med, 51, pp.2789~2792 (2012)
- Waters KA, "Role of NMDA receptors in development of respiratory control", Respir Physiol Neurobiol, 149, pp.123~130 (2005)
- Fokkink WR, "Association of albumin levels with outcome in intravenous immunoglobulin-treated Guillain-Barré syndrome", JAMA Neurol, 74, pp.189~196 (2017)
- Chi X, "Risk factors for mortality in patients with anti-NMDA receptor encephalitis", Acta Neurol Scand, 136, pp.298~304 (2017)
- Dalmau J, "Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma", Ann Neurol, 61, pp.25~36 (2007)
- Sonderen AV, "Predictive value of electroencephalography in anti-NMDA receptor encephalitis", J Neurol Neurosurg Psychiatry, 89, pp.1101~1106 (2018)
- Wang R, "CSF findings in patients with anti-N-methyl-D-aspartate receptor-encephalitis", Seizure, 29, pp.137~142 (2015)
- Gresa-Arribas N, "Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis : a retrospective study", Lancet Neurol, 13, pp.167~177 (2014)
- Lin J, "Neutrophil to lymphocyte ratio may be a helpful marker to evaluate disease activity in NMOSD", Neurol Sci, 38, pp.1859~1863 (2017)
- Wu Y, "Neutrophil-to-lymphocyte ratio(NLR)and platelet-to-lymphocyte ratio(PLR)were associated with disease activity in patients with systemic lupus erythematosus", Int Immunopharmacol, 36, pp.94~99 (2016)
- Bisgaard AK, "The neutrophil-to-lymphocyte ratio as disease actvity marker in multiple sclerosis and optic neuritis", Mult Scler Relat Disord, 18, pp.213~217 (2017)
- Shu Y, "Serum uric acid and anti-N-methyl-D-aspartate receptor encephalitis", Neurochem Int, 108, pp.34~39 (2017)
- Shu Y, "Serum cystatin C and anti-N-methyl-D-aspartate receptor encephalitis", Acta Neurol Scand, 137, pp.515~522 (2018)
- Zhang Y, "Elevated fibrinogen levels in neuromyelitis optica is associated with severity of disease", Neurol Sci, 37, pp.1823~1829 (2016)